DSG2 Expression Detection for Chemoresistant Cancer Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges due to physical barriers formed by epithelial junctions, particularly in ovarian cancer, where desmoglein-2 (DSG2) is overexpressed, contributing to chemoresistance and making it difficult for therapeutics and immune cells to penetrate tumors, necessitating a reliable biomarker for aggressiveness and therapeutic resistance.
Innovation Solution
Detection of elevated DSG2 expression using DSG2 binding reagents such as antibodies or aptamers, followed by quantitative mRNA techniques or immunohistochemistry, to determine chemoresistance, tumor stage, and prognosis, allowing for tailored treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If DSG2 is overexpressed in tumor cells to form tight physical barriers, then structural integrity and exclusion of microbes are improved, but penetration of therapeutics and immune cells is hindered
Solution Approach 1:
The patent uses DSG2 binding reagents (antibodies, aptamers) as intermediaries to detect and quantify DSG2 expression levels on tumor cell surfaces. These reagents bind specifically to DSG2, enabling measurement of the barrier formation without disrupting the tight junctions themselves, thus resolving the contradiction between maintaining structural integrity and assessing chemoresistance risk
Solution Approach 2:
The patent replaces direct mechanical assessment of tight junction integrity with a biochemical detection system. Instead of physically probing the tight barriers, the invention uses molecular binding reagents that chemically interact with DSG2 proteins, substituting mechanical measurement with a sensitive biochemical assay that can detect expression levels without compromising the barrier structure
2Measurement precision
If DSG2 binding reagents are used to detect elevated expression, then identification of chemoresistant cancers is improved, but complexity of detection methods is increased
Solution Approach 1:
The patent employs DSG2 binding reagents that serve multiple functions: they specifically bind to DSG2 for detection, can be used in various assay formats (flow cytometry, immunohistochemistry, ELISA), and provide both qualitative and quantitative information about DSG2 expression. This multi-functionality achieves high measurement precision without requiring multiple different reagents or complex specialized equipment
Solution Approach 2:
The patent detects DSG2 expression by measuring changes in binding reagent interaction with tumor cells. By quantifying the amount of bound reagent through various detection methods (fluorescence intensity, colorimetric signals), the system translates complex molecular interactions into simple, measurable parameters that indicate chemoresistance risk without requiring complex analysis equipment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively identifies chemoresistant cancers and predicts patient survival and treatment response, enabling targeted therapies and improving prognosis by correlating DSG2 expression levels with tumor aggressiveness and survival outcomes.
Implementation Method 1
DSG2 binding reagents can be proteins, such as anti-DSG2 antibodies
Implementation Method 2
or aptamers, or polypeptides (engineered binding proteins)
Data Source
AI summary
The disclosure provides methods of diagnosing, prognosing and stratifying cancers in a patient, comprising detecting elevated expression of desmoglein-2 (DSG-2) in a sample of the cancer and referencing that level to historic data to determine treatment regimen, stage, and prognosis of a patient.